Inadequate control of atherosclerotic cardiovascular disease risk factors in Europe: EUROASPIRE repeats itself

Restricted accessEditorialFirst published online May, 2019

Inadequate control of atherosclerotic cardiovascular disease risk factors in Europe: EUROASPIRE repeats itself

Volume 26, Issue 8https://doi.org/10.1177/2047487319831476

Abstract

Get full access to this article

View all access options for this article.

References

1.

Roth

GA

Huffman

MD

Moran

AE

et al.

Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation 2015; 132: 1667–1678.

2.

Mensah

GA

Wei

GS

Sorlie

PD

et al.

Decline in cardiovascular mortality: Possible causes and implications. Circ Res 2017; 120: 366–380.

3.

Hartley

A

Marshall

DC

Salciccioli

JD

et al.

Trends in mortality from ischemic heart disease and cerebrovascular disease in Europe: 1980 to 2009. Circulation 2016; 133: 1916–1926.

4.

Babb

S

Malarcher

A

Schauer

G

et al.

Quitting smoking among adults – United States, 2000-2015. MMWR Morb Mortal Wkly Rep 2017; 65: 1457–1464.

5.

Ford

ES

Ajani

UA

Croft

JB

et al.

Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med 2007; 356: 2388–2398.

6.

Cholesterol Treatment Trialists’ (CTT) Collaboration Baigent

C

Blackwell

L

et al.

Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670–1681.

7.

Antithrombotic Trialists’ (ATT) Collaboration Baigent

C

Blackwell

L

et al.

Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–1860.

8.

Turnbull F; Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527–1535.

9.

Pyorala

K

De Backer

G

Graham

I

et al.

Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300–1331.

10.

Wood D, De Backer G, Faegerman O et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998; 19: 1434–1503.

11.

De Backer

G

Ambrosioni

E

Borch-Johnsen

K

et al.

European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003; 10: S1–S10.

12.

Graham

I

Atar

D

Borch-Johnsen

K

et al.

European guidelines on cardiovascular disease prevention in clinical practice: Full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14(Suppl. 2): S1–S113.

13.

Perk

J

De Backer

G

Gohlke

H

et al.

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635–1701.

14.

Piepoli

MF

Hoes

AW

Agewall

S

et al.

2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol 2016; 23: NP1–NP96.

15.

Jacobs

AK

Anderson

JL

Halperin

JL

. The evolution and future of ACC/AHA clinical practice guidelines: A 30-year journey: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 64: 1373–1384.

16.

Ibanez

B

James

S

Agewall

S

et al.

ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39: 119–177.

17.

Santos

RD

. Better health literacy can make the difference when control of risk factors for cardiovascular disease and quality of life are concerned. Eur J Prev Cardiol 2017; 24: 1878–1879.

18.

Aaby

A

Friis

K

Christensen

B

et al.

Health literacy is associated with health behaviour and self-reported health: A large population-based study in individuals with cardiovascular disease. Eur J Prev Cardiol 2017; 24: 1880–1888.

19.

Phillips

LS

Branch

WT

Cook

CB

et al.

Clinical inertia. Ann Intern Med 2001; 135: 825–834.

20.

EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997; 18: 1569–1582.

21.

EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554–572.

22.

Kotseva

K

Wood

D

De Backer

G

et al.

EUROASPIRE Study Group. EUROASPIRE III: A survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16: 121–137.

23.

Kotseva

K

Wood

D

De Bacquer

D

et al.

EUROASPIRE Investigators. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016; 23: 636–648.

24.

Kotseva

K

Wood

D

De Bacquer

D

et al.

EUROASPIRE Investigators. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology EUROASPIRE V survey. Eur J Prev Cardiol 2019; 26: 824–835.

25.

Kotseva

K

De Bacquer

D

De Backer

G

et al.

on behalf of the Euroaspire Investigators. Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. Eur J Prev Cardiol 2016; 23: 2007–2018.

26.

Stevens

VJ

Obarzanek

E

Cook

NR

et al.

Trials for the Hypertension Prevention Research Group. Long-term weight loss and changes in blood pressure: Results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001; 134: 1–11.

27.

Whelton

SP

Chin

A

Xin

X

et al.

Effect of aerobic exercise on blood pressure: A meta-analysis of randomized, controlled trials. Ann Intern Med 2002; 136: 493–503.

28.

Grundy

SM

Stone

NJ

Bailey

AL

et al.

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. Epub ahead of print 8 November 2018. DOI: 10.1016/j.jacc.2018.11.003.

29.

Danchin

N

Almahmeed

W

Al-Rasadi

K

et al.

ICLPS Investigators. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS). Eur J Prev Cardiol 2018; 25: 1087–1094.

30.

Connolly

SJ

Eikelboom

JW

Bosch

J

et al.

COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: An international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391: 205–218.

31.

Sabatine

MS

Giugliano

RP

Keech

AC

et al.

FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713–1722.

32.

Ridker

PM

Everett

BM

Thuren

T

et al.

CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377: 1119–1131.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.07 MB